DOYLESTOWN, Pa. , Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it has appointed Dr.
DOYLESTOWN, Pa. , Aug. 10, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and six months ended June
DOYLESTOWN, Pa. , June 14, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that Oren
DOYLESTOWN, Pa. , May 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that Oren
DOYLESTOWN, Pa. , May 15, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today reported
DOYLESTOWN, Pa. , May 08, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today
DOYLESTOWN, Pa. , March 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today
DOYLESTOWN, Pa. , March 16, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that an
DOYLESTOWN, Pa. , March 07, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that Oren
DOYLESTOWN, Pa. , March 01, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that it
